{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:11:55Z","timestamp":1769728315747,"version":"3.49.0"},"reference-count":40,"publisher":"Endocrinology Research Centre","issue":"5","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Von Hippel-Lindau syndrome (FHL) is a rare autosomal dominant disease that leads to the formation of multiple organ tumor syndrome. The pathology is primarily caused by the inactivation of the VHL gene, which is located on chromosome 3 (3p25\/26) and encodes ubiquitin ligase, which destroys hypoxia-induced factor-1\u03b1 (HIF-1\u03b1). The genetic defect leads to the accumulation of HIF-1a protein, activating key carcinogenic pathways, and activated cytokines cause abnormal proliferation of tumor cells and oncogenesis. To date, more than 500 mutations have been registered in VHL. FHL syndrome is characterized by various tumors, including hemangioblastomas of the retina and central nervous system, pheochromocytomas, clear cell renal cell carcinoma, cystic adenoma and others. In the presented clinical description, pheochromocytoma was initially diagnosed in the patient\u2019s mother, and 2 months later in the eldest son. Subsequently, the results of a molecular genetic study made it possible to verify the diagnosis, since in the gene in exon 3 of VHL, a single nucleotide was replaced in the heterozygous state of C.500 G&gt;A, leading to the replacement of the amino acid p.R167Q. Identification of the VHL gene mutation required genetic counseling of all family members, during which a similar mutation was identified in the younger brother. Surgical treatment is the main method of treating FHL syndrome, but advances in genetic research technologies provide new opportunities for the treatment of tumors associated with this syndrome.<\/jats:p>","DOI":"10.14341\/probl13510","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:51:37Z","timestamp":1764838297000},"page":"68-74","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["A Family case of von Hippel-Lindau syndrome"],"prefix":"10.14341","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5811-0024","authenticated-orcid":true,"given":"R. A.","family":"Atanesyan","sequence":"first","affiliation":[{"name":"Stavropol State Medical University;\r\nRegional endocrinological dispensary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-1614","authenticated-orcid":true,"given":"L. Y.","family":"Klimov","sequence":"additional","affiliation":[{"name":"Stavropol State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-3116","authenticated-orcid":true,"given":"T. M.","family":"Vdovina","sequence":"additional","affiliation":[{"name":"Stavropol Regional Clinical Perinatal Center \u21161"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-254X","authenticated-orcid":true,"given":"G. A.","family":"Saneeva","sequence":"additional","affiliation":[{"name":"Stavropol State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0034-8616","authenticated-orcid":true,"given":"E. I.","family":"Andreeva","sequence":"additional","affiliation":[{"name":"Stavropol State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6596-8334","authenticated-orcid":true,"given":"I. K.","family":"Gasparian","sequence":"additional","affiliation":[{"name":"Stavropol State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"ref1","unstructured":"Safronova Yu.V., Glukhov D.V., Strukova S.S., et al. Hippel-Lindau Disease. Oncology Bulletin of the Volga Region. 2016; 4(26): 72\u201375(in Russ.)"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Okada N, Shioya A, Togi S, et al. A Case of Von Hippel-Lindau Disease With Recurrence of Paraganglioma and No Other Associated Symptoms: The Importance of Genetic Testing and Establishing Follow-Up Policies. Cureus 2023; 15(12): e50484. doi: https:\/\/doi.org\/10.7759\/cureus.50484","DOI":"10.7759\/cureus.50484"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Cassol C, Mete O. Endocrine manifestations of von HippelLindau disease. Archives of pathology and laboratory medicine. 2015;139(2):263-268. doi: https:\/\/doi.org\/10.5858\/arpa.2013-0520-RS","DOI":"10.5858\/arpa.2013-0520-RS"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Hudler P, Urbancic M. The Role of VHL in the Development of Von Hippel-Lindau Disease and Erythrocytosis. Genes (Basel). 2022; 13(2):362. doi: https:\/\/doi.org\/10.3390\/genes13020362","DOI":"10.3390\/genes13020362"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer. 2002; 2(9):673-682. doi: https:\/\/doi.org\/10.1038\/nrc885","DOI":"10.1038\/nrc885"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nature Reviews Cancer. 2015;15(1):55-64. doi: https:\/\/doi.org\/10.1038\/nrc3844","DOI":"10.1038\/nrc3844"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"He W, Batty-Stuart S, Lee JE, Ohh M. HIF-1\u03b1 Hydroxyprolines Modulate Oxygen-Dependent Protein Stability Via Single VHL Interface With Comparable Effect on Ubiquitination Rate. Journal of molecular biology. 2021;433(22):167244. doi: https:\/\/doi.org\/10.1016\/j.jmb.2021.167244","DOI":"10.1016\/j.jmb.2021.167244"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Maher ER. Von Hippel-Lindau disease. Current Molecular Medicine. 2004;4(8):833-842. doi: https:\/\/doi.org\/10.2174\/1566524043359827","DOI":"10.2174\/1566524043359827"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gl\u00e4sker S, Vergauwen E, Koch CA, et al. Von Hippel-Lindau Disease: Current Challenges and Future Prospects. Onco Targets and Therapy. 2020;13:5669-5690. doi: https:\/\/doi.org\/10.2147\/OTT.S190753","DOI":"10.2147\/OTT.S190753"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Li Y, Xin X, Song W, et al. VHL syndrome without clear family history: A rare case report and literature review of Chinese patients. Frontiers of Neurology. 2022;13:951054. doi: https:\/\/doi.org\/10.3389\/fneur.2022.951054","DOI":"10.3389\/fneur.2022.951054"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ruppert MD, Gavin M, Mitchell KT, Peiris AN. Ocular Manifestations of von Hippel-Lindau Disease. Cureus. 2019; 11(8):e5319. doi: https:\/\/doi.org\/10.7759\/cureus.5319","DOI":"10.7759\/cureus.5319"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ershova EV, Yukina MYu, Troshina EA, et al. Sindrom fon Khippelya-Lindau. Ozhirenie i metabolizm. 2011;8(2):65-68(in Russ.). doi: https:\/\/doi.org\/10.14341\/2071-8713-4955","DOI":"10.14341\/2071-8713-4955"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Varshney N, Kebede AA, Owusu-Dapaah H, et al. A Review of Von Hippel-Lindau Syndrome. Journal of kidney cancer and VHL. 2017; 4(3):20-29. doi: https:\/\/doi.org\/10.15586\/jkcvhl.2017.88","DOI":"10.15586\/jkcvhl.2017.88"},{"key":"ref14","unstructured":"\u0411\u0435\u043b\u044c\u0446\u0435\u0432\u0438\u0447, \u0414. \u0413. \u041e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u043e\u0431\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u0438 \u0432\u0435\u0434\u0435\u043d\u0438\u044f \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0441 \u0444\u0435\u043e\u0445\u0440\u043e\u043c\u043e\u0446\u0438\u0442\u043e\u043c\u043e\u0439 \/\/ \u0414\u043e\u043a\u0442\u043e\u0440.\u0420\u0443. \u2014 2009. \u2014 \u2116 6-2(50). \u2014 \u0421. 30-34."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Choi H, Kim KJ, Hong N, et al. Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population. Endocrinology and Metabolism (Seoul). 2020; 35(4):858-872. doi: https:\/\/doi.org\/10.3803\/EnM.2020.683","DOI":"10.3803\/EnM.2020.683"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Research. 2019;47(D1):D941-D947. doi: https:\/\/doi.org\/10.1093\/nar\/gky1015","DOI":"10.1093\/nar\/gky1015"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery. 2012;2(5):401-404. doi: https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Maher ER, Sandford RN. Von Hippel-Lindau Disease: An Update. Current Genetics Medicine Reporte. 2019;7:227\u2013235. doi: https:\/\/doi.org\/10.1007\/s40142-019-00180-9","DOI":"10.1007\/s40142-019-00180-9"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Shmueli MD, Schnaider L, Rosenblum D, et al. Structural Insights into the Folding Defects of Oncogenic pVHL Lead to Correction of Its Function In Vitro. PLoS ONE. 2013:8(6):e66333. doi: https:\/\/doi.org\/10.1371\/journal.pone.0066333","DOI":"10.1371\/journal.pone.0066333"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Crespigio J, Berbel LCL, Dias MA, et al. Von HippelLindau disease: a single gene, several hereditary tumors. Journal of Endocrinological Investigation. 2018;41(1):21-31. doi: https:\/\/doi.org\/10.1007\/s40618-017-0683-1","DOI":"10.1007\/s40618-017-0683-1"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Baudin E, Habra MA, Deschamps F, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. European Journal of Endocrinology. 2014; 171(3):R111-R122. doi: https:\/\/doi.org\/10.1530\/EJE-14-0113","DOI":"10.1530\/EJE-14-0113"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Pinato DJ, Ramachandran R, Toussi ST, et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. British Journal of Cancer. 2013;108(2):429-437. doi: https:\/\/doi.org\/10.1038\/bjc.2012.538","DOI":"10.1038\/bjc.2012.538"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Barsukov AV, Korneichuk NN, Pesikin IN, et al. Noradrenalin-sekretiruyushchaya paraganglioma: opisanie klinicheskogo sluchaya. Arterial\u2019naya gipertenziya. 2017;23(3):231\u2013242 (in Russ.). doi: https:\/\/doi.org\/10.18705\/1607-419X-2017-23-3-231-242","DOI":"10.18705\/1607-419X-2017-23-3-231-242"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Iukina MI, Tiul\u2019pakov AN, Troshina EA, Bel\u2019tsevich DG. Von Hippel-Lindau disease (VHL-syndrome). Problems of Endocrinology. 2012;58(2):34-41. (in Russ.) doi: https:\/\/doi.org\/10.14341\/probl201258234-41","DOI":"10.14341\/probl201258234-41"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Louise M Binderup M, Smerdel M, Borgwadt L, et al. von HippelLindau disease: Updated guideline for diagnosis and surveillance. European Journal of Medical Genetics. 2022; 65(8):104538. doi: https:\/\/doi.org\/10.1016\/j.ejmg.2022.104538","DOI":"10.1016\/j.ejmg.2022.104538"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Zhang K, Qiu J, Yang W, et al. Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients. Journal of Medical Genetics. 2022;59(10):951-956. doi: https:\/\/doi.org\/10.1136\/jmedgenet-2021-108216","DOI":"10.1136\/jmedgenet-2021-108216"},{"key":"ref27","unstructured":"Mokhort TV, Velesevich EI, Mokhort EG. Feokhromotsitoma: sovremennye podkhody k diagnostike i lecheniyu.\/ Meditsinskie novosti. 2016;\u21164:S.3-10. (in Russ.)"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Mete O, Tischler AS, de Krijger R, et al. Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. Archives of pathology and laboratory medicine. 2014;138(2):182-188. doi: https:\/\/doi.org\/10.5858\/arpa.2012-0551-OA","DOI":"10.5858\/arpa.2012-0551-OA"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Albi\u00f1ana V, Escribano RMJ, Soler I, et al. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet Journal of Rare Diseases. 2017;12(1):122. doi: https:\/\/doi.org\/10.1186\/s13023-017-0664-7","DOI":"10.1186\/s13023-017-0664-7"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Semenza GL. Targeting HIF-1 for cancer therapy. Nature reviews. Cancer. 2003;3(10):721-732. doi: https:\/\/doi.org\/10.1038\/nrc1187","DOI":"10.1038\/nrc1187"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Jimenez C, Cabanillas ME, Santarpia L, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. The Journal of clinical endocrinology and metabolism. 2009;94(2):386-391. doi: https:\/\/doi.org\/10.1210\/jc.2008-1972","DOI":"10.1210\/jc.2008-1972"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sanchez DJ, Simon MC. Transcriptional control of kidney cancer. Science. 2018;361(6399):226-227. doi: https:\/\/doi.org\/10.1126\/science.aau4385","DOI":"10.1126\/science.aau4385"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Deeks E.D. Belzutifan: First Approval. Drugs. 2021; 81:1921\u20131927. doi: https:\/\/doi.org\/10.1007\/s40265-021-01606-x","DOI":"10.1007\/s40265-021-01606-x"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Sanford T, Gomella PT, Siddiqui R, et al. Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. Urologic Oncology. 2021; 39(2):134.e1-134.e8. doi: https:\/\/doi.org\/10.1016\/j.urolonc.2020.11.019","DOI":"10.1016\/j.urolonc.2020.11.019"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Durante C, Heged\u00fcs L, Czarniecka A, et al. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. European Thyroid Journal. 2023;12(5):e230067. doi: https:\/\/doi.org\/10.1530\/ETJ-23-0067","DOI":"10.1530\/ETJ-23-0067"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. PLoS One. 2008;3(11):e3801. doi: https:\/\/doi.org\/10.1371\/journal.pone.0003801","DOI":"10.1371\/journal.pone.0003801"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Hudler P, Urbancic M. The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis. Genes (Basel). 2022;13(2):362. doi: https:\/\/doi.org\/10.3390\/genes13020362","DOI":"10.3390\/genes13020362"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Fan X, Wang S, Chen T, et al. Von-Hipple Lindau syndrome with family history: a case report and seventeen years follow-up study. Frontiers in oncology. 2024;14:1360942. doi: https:\/\/doi.org\/10.3389\/fonc.2024.1360942","DOI":"10.3389\/fonc.2024.1360942"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Castro-Teles J, Sousa-Pinto B, Rebelo S, Pignatelli D. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack. Endocrine Connections. 2021;10(11):R293-R304. doi: https:\/\/doi.org\/10.1530\/EC-21-0294","DOI":"10.1530\/EC-21-0294"},{"key":"ref40","unstructured":"Murro V, Lippera M, Mucciolo DP, et al. Outcome and genetic analysis of patients affected by retinal capillary hemangioblastoma"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13510\/10915","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:40:26Z","timestamp":1769686826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13510","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}